Valeant (VRX) Investors Should Be Focused on Earnings Not Upcoming Product Catalysts - Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Valeant Pharma (VRX) Brodalumab Briefing Docs Posted; Concerns Linger
July 15, 2016 8:10 AM EDTBriefing docs for Valeant's (NYSE: VRX) brodalumab posted by the U.S. FDA. They can be accessed... More
Citron's Left Keeps Changing His Position on Valeant (VRX) - Ackman
July 14, 2016 12:32 PM EDTOn CNBC, Bill Ackman commented on Citron Research's Andrew Left new short on Valeant Pharma (NYSE: VRX), which was highlighted yesterday. Ackman highlights that Left was first short, then long a few months ago, and now short again. He said Left is just... More
Bill Ackman said Valeant Pharma (VRX) won't sell Bausch & Lomb, will build out it
July 14, 2016 12:28 PM EDTOn CNBC, Bill Ackman said Valeant Pharma (NYSE: VRX) won't sell Bausch & Lomb will build out it; company could eventually change its name to Bausch & Lomb.
... MoreBill Ackman expects 'very significant' Valeant Pharma (VRX) assets sales by year-end
July 14, 2016 12:25 PM EDTOn CNBC, Bill Ackman said he expects 'very significant' Valeant Pharma (NYSE: VRX) assets sales by year-end.
... MoreAckman Feels 'Sad' for Michael Pearson on Forced Valeant (VRX) Sale
July 14, 2016 12:23 PM EDTOn CNBC, Bill Ackman said he feels 'sad' for Michael Pearson for being forced to sell-out of Valeant Pharma (NYSE: VRX) related to tax purposes on a margin call.
... MoreValeant Pharma (VRX) call volume and volatility up into CNBC appearance by Ackman
July 14, 2016 11:51 AM EDTValeant Pharma (NYSE: VRX) July 22.5 and 23 calls are active on total call volume of 36K contracts (20K puts) into a CNBC appearance by large shareholder Bill Ackman. July call option implied volatility is at 113, August is at 101; compared to its 52-week range of 29 to 172.
... MorePre-Open Stock Movers 07/14: (SUNW) (CREE) (YUM) (JPM) Higher; (ACHN) (LXU) (SUM) Lower (more...)
July 14, 2016 9:27 AM EDTToday's Pre-Open Stock Mover:
Sunworks, Inc. (NASDAQ: SUNW) 16.5% HIGHER; announced today that Amazon has contracted with Sunworks to oversee the rooftop solar installations of 1 Megawatt mounted projects in both Reno, Nevada and Windsor, Connecticut. Sunworks was selected based on its history, experience and reputation as a quality solar provider.
Cree, Inc. (Nasdaq: CREE) 9.4% HIGHER; announced execution of a definitive agreement to sell its Wolfspeed... More
Valeant says ex-CEO Pearson remains a significant shareholder
July 14, 2016 9:14 AM EDT(Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc (NYSE: VRX) said on Thursday its former Chief Executive Michael Pearson, who has sold shares worth almost $100 million, remained a significant shareholder.
Pearson, who was replaced by Joseph Papa in May, still holds more than 3.5 million shares - valued at more than $75 million based on Wednesday's close of $21.62.
"While I trimmed my ownership position for personal reasons, I plan on holding my remaining shares... More
Valeant Pharma (VRX) Shares Rise After Clarifying Recent Pearson Stock, Options Sales
July 14, 2016 9:00 AM EDTValeant Pharma (NYSE: VRX) shares are indicated higher in early trading Thursday after the company issued commentary on recent stock transactions conducted by former CEO Mike Pearson. The stock is up over 3 percent.
... MoreBill Ackman Will Be on CNBC's Halftime Report Today (VRX) (HLF)
July 14, 2016 8:55 AM EDTBill Ackman will be on CNBC's Halftime Report at noon. Although the agenda wasn't disclosed, he will likely discuss Herbalife (NYSE: HLF) and Valeant Pharma (NYSE: VRX).
Today on @HalftimeReport at noon ET: Bill Ackman joins @ScottWapnerCNBC and the traders LIVE pic.twitter.com/kGGLLRrzmO
CNBC Now (@CNBCnow) July 14, 2016... MoreValeant Pharma (VRX) Comments on Recent Stock Transactions by Former CEO Pearson
July 14, 2016 8:51 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) today commented on recent stock transactions made by Valeant's former chief executive officer, J. Michael Pearson. The Company understands that Mr. Pearson exercised and sold options representing approximately 4.4 million shares, which would expire within the next 12 months, and sold approximately 411,000 shares of common stock in June and July to satisfy tax obligations with respect to the 2015 margin sale conducted by Goldman Sachs, and for additional liquidity. Mr. Pearson remains a significant Valeant... More
Stocks with Implied Volatility Movement
July 14, 2016 5:18 AM EDTValeant Pharma (NYSE: VRX) had wide implied volatility movement
... MoreValeant Pharma (VRX) volatility spikes after Left said to take new short
July 13, 2016 1:09 PM EDTValeant Pharma (NYSE: VRX) July call option implied volatility is at 123, compared to closing level of 82 last night, August is at 94, compared to a closing level of 86, after Citron's Andrew Left said to take a new short stake and says worth $0.
... MoreUPDATE: Citron's Andrew Left Says Short Position on Valeant Pharma (VRX) 'Small' - Bloomberg
July 13, 2016 1:07 PM EDT(Updated - July 13, 2016 1:09 PM EDT)
Citron's Andrew Left said in a Bloomberg telephone interview that is short position on Valeant Pharma (NYSE: VRX) is small. The position has been held for a few weeks and was described as "nothing substantial."
... MoreCitron's Left Said to Take New Short Stake in Valeant Pharma (VRX); Says Worth $0
July 13, 2016 12:48 PM EDT(Updated - July 13, 2016 12:52 PM EDT)
Citron's Andrew Left said to take a new short stake in Valeant Pharma (NYSE: VRX).
UPDATE - According to... More
Citron Research calling Valeant Pharma (VRX) a zero
July 13, 2016 12:48 PM EDTCitron Research calling Valeant Pharma (NYSE: VRX) a zero
Have Valeant Pharma (VRX) Shareholders Finally Capitulated?
July 13, 2016 12:24 PM EDTValeant Pharma (NYSE: VRX) is gaining as earlier reported liquidation at Sequoia Fund and news that ex-CEO... More
Streetinsider.com's Hot Lunchtime Reads 7/13: (VRX) (EVH) (ADTN) (FB)
July 13, 2016 12:06 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Facebook (FB) Mentioned Cautiously at Citron Research Related to Pokemon Go ->... More
Valeant (VRX): Pearson Recently Exercised Options, Required to Hold 1M Shares for 2 Years
July 13, 2016 11:51 AM EDTValeant Pharma (NYSE: VRX) issued a statement to StreetInsider.com on reports ex-CEO, J. Michael Pearson, sold 5 million... More
Valeant Pharma (VRX) Pearson Said to Have Sold 5M Shares - CNBC
July 13, 2016 11:28 AM EDTCNBC Scott Wapner reports Valeant Pharma (NYSE: VRX) Pearson unloaded much more of his holdings than originally thought. Nearly 5m shares and in the money options worth $96.8m.
... More
RBC Highlights Next Week's Key Events for Valeant Pharma (VRX)
July 13, 2016 8:19 AM EDTRBC affirms Valeant Pharma (NYSE: VRX) at Sector Perform with a price target of $33 as the firm provides a schedule and commentary of what investors should focus on next week for the company.
RBC analyst Douglas Miehm noted:
Upcoming PDUFA dates: Oral Relistor (July 19) and latanoprostene bunod (July 21). Valeant has two PDUFA dates next week. The first, on July 19, is for Oral Relistor for the treatment of opioid-induced constipation. Following the FDA's delay in PDUFA date, we remain confident that Oral Relistor should see approval in or... MoreLong-Time Valeant Pharma (VRX) Holder Sequoia Fund Exits Position
July 13, 2016 6:09 AM EDTValeant Pharma (NYSE: VRX) shares are on watch Wednesday following news that long-time holder Sequoia Fund exited its position.
Valeant Pharma (VRX) volatility at lower end of eight month range, Sequoia Fund exited position
July 13, 2016 6:05 AM EDTValeant Pharma (NYSE: VRX) is recently up 21c to $23.43 in the premarket on Sequoia Fund, the longtime and once the largest investor in Valeant exiting the investment last month. July call option implied volatility is at 82, August is at 86; compared to its 52-week range of 29 to
... MoreGuggenheim Highlights Latest Specialty Pharma Short Interest Data (HZNP) (VRX) (PRGO) (SHPG) (AGN)
July 12, 2016 4:59 PM EDTGuggenheim analyst Louise Chen broke down the latest short interest data (6/30/2016) for the Specialty Pharmaceutical sector and other key Pharma/Biotech players.
The analyst notes stocks with the largest increase in short interest is AcelRx Pharmaceuticals (NASDAQ: ACRX) at +30.9%, followed by Horizon... More
